RESULTS OF INTRAMYOCARDIAL ADMINISTRATION OF A MONONUCLEAR FRACTION OF AUTOLOGOUS BONE MARROW CELLS IN CHD PATIENTS WITH CONCOMITANT CARDIAINSUFFICIENCY
https://doi.org/10.15825/1995-1191-2013-3-83-91
Abstract
Aim. Evaluation of long-term results of drug therapy and intramyocardial administration of a mononuclear fraction of bone marrow cells in CHD patients with chronic cardiac insufficiency. Materials and methods. 109 patients were randomized into two groups by using an envelope method. Intramyocardial administration of a mononuclear fraction of autologous bone marrow cells and cardiac insufficiency therapy were performed for the 1st group (n = 55), while the 2nd group (n = 54) received drug therapy only. All patients underwent clinical examination at admission and at 6 and 12 months after the onset of the study. Results. In the 1st group the angina functional class was reliably lowered (from 3.3 ± 0.2 at the onset of the study down to 2.5 ± 0.1 after 12 months). The distance covered during a 6-minute walk test increased from the initial 185 ± 39 meters up to 359 ± 69 me- ters by the end of the 12th month. The angina class decreased from 3.1 ± 0.4 at the onset of the study down to 1.6 ± 0.4 by the end of the 12th month. Minnesota Life Quality Index reduced from 65.3 ± 21 points down to 22.4 ± 6 points in the first group, while in the control one it decreased down to 59.9 ± 16 points. On the contrary, cardiac insufficiency in patients of the second group tended to continually progress: from NYHA FC 3.5 ± 0.1 at the beginning of the study up to 3.9 ± 0.1 in the course of 12-month observation. The angina class remained the same (3.5 ± 0.5 at the beginning and 3.5 ± 0.4 after 12 months respectively). Conclusion. Intramyocardial implantation of a mononuclear fraction of autologous bone marrow cells is a safe method that contributes to the improvement of the left ventricular function, clinical data and prognosis.
About the Authors
A. M. Cherniavsky
Center for Aorta & Coronary Arteries Cardiac Surgery (Head – doct. of med. sci., professor A.M. Cherniavsky), Ye.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Novosibirsk, Russian Federation
Russian Federation
Russian Federation
Ye. N. Kliever
Center for Aorta & Coronary Arteries Cardiac Surgery (Head – doct. of med. sci., professor A.M. Cherniavsky), Ye.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Novosibirsk, Russian Federation
Russian Federation
Russian Federation
Ye. A. Pokushalov
Center for Surgical Arrhythmology (Head – doct. of med. sci. Ye.A. Pokushalov), Ye.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Novosibirsk, Russian Federation
Russian Federation
Russian Federation
A. B. Romanov
Center for Surgical Arrhythmology (Head – doct. of med. sci. Ye.A. Pokushalov), Ye.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Novosibirsk, Russian Federation
Russian Federation
Russian Federation
I. N. Terekhov
Department of Radiology & Functional Diagnostics X-Ray CAT Division (Head – cand. of med. sci. V.P. Kurbatov) Ye.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Novosibirsk, Russian Federation
Russian Federation
Russian Federation
Ye. E. Kliever
Electron Microscopy&Pathomorphology Laboratory (Head – doct. of med. sci. A.M. Volkov),
Ye.N. Meshalkin Novosibirsk Research Institute of Circulation Pathology, Novosibirsk, Russian Federation
Russian Federation
Russian Federation
References
1. Beeres S., Bax J., Dibbets P., Stokkel M. Effect of In- tramyocardial Injection of Autologous Bone Marrow– Derived Mononuclear Cells on Perfusion, Function, and Viability in Patients with Drug-Refractory Chronic
2. Ischemia. J. Nucl. Med. 2006; 47: 574–580.
3. Fuchs S., Satler LF., Kornowski R. Catheter-based auto- logous bone marrow myocardial injection in no-option patients with advanced coronary artery disease. J Am Coll Cardiol. 2003; 41: 1721–1724.
4. Izawa H., Kondo T., Usui A., Yamamoto K. Clinical protocol for angiogenesis by intramyocardial injection of auto- logous bone marrow mononuclear cells in patients with se- vere coronary artery disease. Circ. J. 2006; 70: 1180–1183.
5. Perin E.C., Dohmann H.F., Borojevic R. Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circu- lation. 2004; 110 (suppl II): 213–218.
6. Perin E.C., Silva G.V., Sarmento-Leite R. Assessing myocardial viability and infarct transmurality with left ventricular electromechanical mapping in patients with stable coronary artery disease: validation by delayed- enhancement magnetic resonance imaging. Circulation. 2002; 106: 957–961.
7. Tse H., Kwong Y., Chan J., Lo G. Angiogenesis in ischa- emic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet. 2003; 361: 47–49.
8. Dohmann H., Silva S., Souza A. Bonemarrow mononu- clear cell therapy of severe ischemic heart failure. C. R. Biologies. 2007; 330: 543–549.
9. Fuchs S., Satler L., Kornowski R. Catheterbased autolo- gous bone marrow myocardial injection in nooption pati- ents with advanced coronary artery disease: a feasibility study. J. Am. Coll. Cardiol. 2003; 41: 1721–1724.
10. Fuchs S., Kornowski R., Weisz G. Safety and feasibility of transendocardial autologous bone-marrow cell trans- plantation in patients with advanced heart disease. Am. J. Cardiol. 2006; 97: 823–829.
11. Gepstein L., Hayam G., Ben-Haim S.A. A novel method for nonfluoroscopic catheterbased electroanatomical mapping of the heart. In vitro and in vivo accuracy re- sults. Circulation. 1997; 95: 1611–1622.
12. Berman D.S., Hachamovitch R., Kiat J.A. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99m sestamibi myo- cardial perfusion single-photon emission computed tomography. J. Am Coll. Cardiol. 1995; 26: 639–647.
13. Liu Y., Guo J., Zhang P. Bone marrow mononuclear cell transplantation into heart elevates the expression of an- giogenic factors. Microvasc. Res. 2004; 68: 156–160.
14. Orlic D., Hill J., Arai A. Stem cells for myocardial re- generation. Circ Res. 2002; 91: 1092–1102.
15. Silva G., Perin E., Dohmann H. Catheter-based tran- sendocardial delivery of autologous bone-marrow- derived mononuclear cells in patients listed for heart transplantation. Texas Heart Inst. 2004; 31: 214–219.
16. Beeres S., Bax J., Dibbets-Schneider P., Stokkel M. Sus- tained effect of autologous bone marrow mononuclear cell injection in patients with refractory angina pecto- ris and chronic myocardial ischemia: Twelve-month follow-up results. Am. Heart J. 2006; 152: 11–16.
Review
For citations:
Cherniavsky A.M., Kliever Ye.N., Pokushalov Ye.A., Romanov A.B., Terekhov I.N., Kliever Ye.E. RESULTS OF INTRAMYOCARDIAL ADMINISTRATION OF A MONONUCLEAR FRACTION OF AUTOLOGOUS BONE MARROW CELLS IN CHD PATIENTS WITH CONCOMITANT CARDIAINSUFFICIENCY. Russian Journal of Transplantology and Artificial Organs. 2013;15(3):83-91. (In Russ.) https://doi.org/10.15825/1995-1191-2013-3-83-91
Views:
1299
Email this article 